RxDoctor Payments Data

Catherine Gong, MD

Internal Medicine · Brooklyn, NYNPI 1174142392

Payments from drug & device makers

$3,509in general payments, 2019–2025

Across 126 payments — averaging $27.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$677
  • Boehringer Ingelheim$475
  • Amgen$393
  • Madrigal Pharmaceuticals$256
  • IBSA Pharma Inc.$240
  • GSK$229
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,509 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$7,311
Medicare patients
24
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin126$91,407
Diclofenac Epolamine100$71,409
VascepaIcosapent Ethyl195$67,775
EliquisApixaban50$29,423
ProliaDenosumab17$27,963
VemlidyTenofovir Alafenamide17$24,354
JanuviaSitagliptin Phosphate38$23,852
RybelsusSemaglutide21$22,709
OzempicSemaglutide18$17,168
XareltoRivaroxaban23$14,533
Tresiba Flextouch U-200Insulin Degludec22$11,793
LinzessLinaclotide21$11,372
FarxigaDapagliflozin Propanediol15$9,379
JanumetSitagliptin Phos/Metformin Hcl14$9,226
Diclofenac Sodium41$8,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$475$91,407126 claims
Novo NordiskRybelsus, Ozempic$86$39,87739 claims
MerckJanuvia, Janumet$45$33,07852 claims
PfizerEliquis$173$29,42350 claims
AmgenProlia$393$27,96317 claims
GileadVemlidy$677$24,35417 claims
AbbVieLinzess$86$11,37221 claims
AstraZenecaFarxiga$16$9,37915 claims
GSKShingrix$229$2,36818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →